Caris' scientific experts contribute to the advancement of science at various symposia and conferences worldwide. Please enjoy these featured presentations.
2015 Genitourinary Cancers Symposium (ASCO-GU)
2015 Gastrointestinal Cancers Symposium (ASCO-GI)
2014 American Society of Clinical Oncology (ASCO) Annual Meeting
2014 Genitourinary Cancers Symposium (ASCO-GU)
2014 Gastrointestinal Cancers Symposium (ASCO-GI)
Read an Oncology Times article, featuring Caris’ Dr. Zoran Gatalica, about how tumor profiling is changing treatment approaches for CUP patients
2013 San Antonio Breast Cancer Symposium (SABCS)
2013 Society for Neuro-Oncology (SNO) Conference
2013 Association for Molecular Pathology (AMP)
2013 European Cancer Congress (ECCO)
Molecular Profiling of Cancers of Unknown Primary Site (CUP): Paradigm Shift in Management of CUP
2013 American Society of Clinical Oncology (ASCO) Annual Meeting
The objective of this prospective pilot study was to determine if treatment selected by molecular profiling (MP) of metastatic breast cancer (MBC) tumors at time of disease progression provides greater clinical benefit than empiric treatment selection. This study demonstrates the feasibility of a highly multiplexed genomic and proteomic MP study for treatment selection in a timely fashion. Patient-specific target driven treatment selection based on MP of a metastatic lesion provided clinical benefit for 10 of 25 heavily pretreated MBC pts.
Glioblastoma multiforme (GBM), the most aggressive CNS cancer, has limited e¬ffective therapeutic options, with underlying molecular heterogeneity contributing to the differences in treatment response. This study was designed to interrogate biomarkers from a large cohort of GBM patients to seek therapeutic implications. By profiling tumor biomarkers from a large cohort of GBM patients using validated assays in a single reference laboratory, the vast molecular heterogeneity of GBM was demonstrated and the importance of individualized therapy based on a patient’s unique tumor profile was highlighted. Incorporating a comprehensive biomarker analysis into clinical management of this aggressive cancer allows for an informed selection of more effective therapies.
2013 International Society for Extracellular Vesicles (ISEV)
2013 Gastrointestinal Cancers Symposium (ASCO-GI)
For patients (pts) with advanced PBC who are able to pursue additional therapy, treatment selection is often empiric and clinical benefits are usually modest. Our goal was to study clinical outcomes of MP-guided treatment in advanced PBC. This retrospective analysis included pts with advanced PBC whose tissue samples underwent MP (IHC, microarray [MA], and sequencing analyses) using Target Now (Caris Life Sciences, Irving, TX). These pts received ≥1 lines of therapy for advanced PBC before their treatment was guided by MP.
Check out recent presentations from the Caris Life Sciences® 2012 ASCO Symposium
- Dr. Daniel Von Hoff presents at Caris Life Sciences 2012 ASCO Symposium (1 of 3)
- Dr. Daniel Von Hoff presents at Caris Life Sciences 2012 ASCO Symposium (2 of 3)
- Dr. Daniel Von Hoff presents at Caris Life Sciences 2012 ASCO Symposium (3 of 3)
- Dr. Michael Castro presents at Caris Life Sciences 2012 ASCO Symposium
- Dr. Charles Myers III presents at Caris Life Sciences 2012 ASCO Symposium
- Dr. Glen J. Weiss presents at Caris Life Sciences 2012 ASCO Symposium
- Dr. Brian Van Tine presents at Caris Life Sciences 2012 ASCO Symposium
The opinions expressed in these videos are the opinions of the speakers and do not necessarily reflect the viewpoints of Caris Life Sciences. Caris Life Sciences is not responsible for the accuracy of the content contained in these videos.
In Bring on the biomarkers, personalized medicine advocate and expert Dr. George Poste argues that the dismal patchwork of fragmented research on disease-associated biomarkers should be replaced by a coordinated “big science” approach. The article appears in the January 13, 2011, issue of Nature.
Read Dr. George Poste's keynote presentation at the Montreux Symposium on Personalized Medicine in Switzerland. The speech occurred on November 10, 2010, and covered the opportunities and challenges presented by the evolution of personalized medicine. Topics covered included:
- New Value Propositions in Healthcare
- Mapping Genetic Predisposition to Disease
- The Progressive Evolution of Personalized Healthcare
- Biomarkers, Biosignatures and Molecular Diagnostics: The Key Value Drivers for Personalized Medicine, Improved Healthcare and Maximizing Wellness
- The Value of Blood-Based Diagnostic Profiling
- Remote Health Status Monitoring
- Biosignature Profiling ViaSensors and Devices
- Genes and Intellectual Property
- The High Information Content (Complexity) of Biological Datasets
- Leveraging the Potential of Molecular Medicine
Download the keynote presentation from the Burrill Conference on Personalized Medicine presented on September 17, 2010, by Dr. George Poste. The presentation provided a broad perspective on the multiple dimensions of biomarker validation from specimen acquisition to reimbursement to the importance of social media in reaching patients.
Key points of the presentation included:
- Major challenges in healthcare
- New priorities in biomedical innovation
- Optimizing the efficiency of healthcare delivery and maximizing wellness
- Discovery, validation and qualification of biomarkers
- The key strategic elements in the evolution of healthcare
Read and view a presentation from Dr. Jonathan Knowles, PhD. Dr. Knowles was a featured presenter, on behalf of the Finnish Institute of Molecular Medicine, at the second annual Worldwide Innovative Networking (WIN) Symposium in Paris, France.
Dr. Knowles' presentation addressed emerging research findings in the development of cancer testing technologies that have the potential to make a dramatic impact on the lives of patients. He delivered this talk on Thursday, July 8, 2010. The abridged transcript and PowerPoint presentation of the speech are available:
- Personalized Therapies for Cancer Patients: Dream, Vision or Immediate Necessity? (abridged transcript)
- Personalized Therapies for Cancer Patients: Dream, Vision or Immediate Necessity? (PowerPoint presentation)
Download Dr. George Poste's presentation about challenges and opportunities in cancer detection and diagnosis. This presentation addressed:
- The imperative to achieve earlier detection and diagnosis
- The role of disease-associated biomarkers as drivers in the future healthcare value chain
- The cancer biomarker challenge
This program was presented on May 21, 2010, at the National Cancer Institute.
“WE INTEND TO HELP RELIEVE THE SUFFERING OF AS MANY PEOPLE AS POSSIBLE”
David D. Halbert Chairman & CEO